205 related articles for article (PubMed ID: 37974028)
1. Additivity predicts the efficacy of most approved combination therapies for advanced cancer.
Hwangbo H; Patterson SC; Dai A; Plana D; Palmer AC
Nat Cancer; 2023 Dec; 4(12):1693-1704. PubMed ID: 37974028
[TBL] [Abstract][Full Text] [Related]
2. Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.
Palmer AC; Izar B; Hwangbo H; Sorger PK
Clin Cancer Res; 2022 Jan; 28(2):368-377. PubMed ID: 35045958
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
4. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
5. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.
Palmer AC; Sorger PK
Cell; 2017 Dec; 171(7):1678-1691.e13. PubMed ID: 29245013
[TBL] [Abstract][Full Text] [Related]
6. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs.
Abd El-Hafeez T; Shams MY; Elshaier YAMM; Farghaly HM; Hassanien AE
Sci Rep; 2024 Jan; 14(1):2428. PubMed ID: 38287066
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
8. In silico drug combination discovery for personalized cancer therapy.
Jeon M; Kim S; Park S; Lee H; Kang J
BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials.
Schmidt EV; Chisamore MJ; Chaney MF; Maradeo ME; Anderson J; Baltus GA; Pinheiro EM; Uebele VN
JAMA Netw Open; 2020 Feb; 3(2):e1920833. PubMed ID: 32049290
[TBL] [Abstract][Full Text] [Related]
12. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
He Q; Li Q; Lv F; Kaitin KI; Shao L
Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
14. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.
Teicher BA
Curr Opin Pharmacol; 2010 Aug; 10(4):397-404. PubMed ID: 20547104
[TBL] [Abstract][Full Text] [Related]
15. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
Tkaczuk KH
Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
[TBL] [Abstract][Full Text] [Related]
16. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
19. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
20. The use of combinations of monoclonal antibodies in clinical oncology.
Henricks LM; Schellens JH; Huitema AD; Beijnen JH
Cancer Treat Rev; 2015 Dec; 41(10):859-67. PubMed ID: 26547132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
